Gleason score predicts androgen independent progression after androgen deprivation therapy

European Urology

Volumn 42, Issue 1, 2002, Pages 12-17

  Benaim, E A ^a,b   Pace, C M ^b   Roehrborn, C G ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Oral and Maxillofacial Surgery   (United States)

Author keywords

Androgen antagonists; Biological neoplasms; Castration; Hormone dependent therapy; Male; Prostatic neoplasm; Tumor markers

Indexed keywords

ANTIANDROGEN; GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ANDROGEN INDEPENDENT PROSTATE CANCER; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CASTRATION; DISEASE COURSE; GLEASON SCORE; HISTOLOGY; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; SCORING SYSTEM;

AGED; ANDROGEN ANTAGONISTS; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0036662309     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(02)00238-5     Document Type: Article

References (20)

1. Crawford ED, Blumenstein BA, Goodman PJ, Davis MA, Eisenberger MA, McLeod DG et al. Leuprolide with and without flutamide in advanced prostate cancer. Cancer 1990;66:1039-44.
2. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339:1036-42.
3. Denis LJ, Keuppens F, Smith PH, Whelan P, de Moura JL, Newling D et al. Maximal androgen blockade: Final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Eur Urol 1998;33:144-51.
4. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New Eng J Med 1989;321(7):419-24.
5. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974;111:58-64.
6. Epstein JI, Charmichael M, Partin AW, Walsh PC. Is tumor volume and independent predictor of progression after radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of follow-up. J Urol 1993;149:1478-81.
7. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE et al. Combination of prostate-specific antigen, a multi-institutional update, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. JAMA 1997;277:1445-51.
8. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-74.
9. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7.
10. Stamey TA. McNeal JE, Yemoto CM, Sigal BM, Johnstone IM. Biological determinants of cancer progression in men with prostate cancer. JAMA 1999:281:1395-400.
11. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55-74 years at diagnosis managed conserva tively for clinically localized prostate cancer. JAMA 1998;280:975-80.
12. Chodak GW. The role of watchful waiting in the management of localized prostate cancer. J Urol 1994;152:1766-8.
13. Chodak GW, Vogelzang NJ, Caplan RJ, Soloway M, Smith JA. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. JAMA 1991;265:618-21.
14. Cooper EH. Armitage TG, Robinson MR, Newling DW. Richards BR, Smith PH et al. Prostatic specific antigen and the prediction of prognosis in metastatic prostatic cancer. Cancer 1990;66:1025-8.
15. Matzkin H, Lewyshon O, Ayalon D, Braf Z. Changes in prostate-specific markers under chronic gonadotrophin-releasing hormone analogue treatment of state D prostatic cancer. Cancer 1989;63:1287-91.
16. Miller JI, Ahmann FR, Drach GW, Emerson SS, Bottaccini MR. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J Urol 1992;147:956-61.
17. Sylvester RJ, Denis L, de Voogt H. The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group. Eur Urol 1998;33:134-43.
18. Eisenberger MA, Crawford ED, Wolf M, Blumenstein B, McLeod DG, Benson R. Prognostic factors in stage D2 prostate cancer; important implications for future trials: Results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study: 0036. Semin Oncol 1994;21:613-9.
19. Moul JW. Treatment options for prostate cancer: Part 1-stage, grade, PSA, and changes in the 1990s. Am J Managed Care 1998;4:1031-6.
20. Stephenson R. Prostate cancer trends in the PSA era: Data from the SEER Program. AUA News 1997;15-22.